Vumerity (Bafcitelin) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. [1]
What is Vumerity's mechanism of action?
Vumerity works by reducing the number of relapses in individuals with relapsing forms of MS. It is believed to exert its therapeutic effect by activating the transcription factor Nrf2, which plays a role in cellular protection against oxidative stress and inflammation. [1]
When did Vumerity receive FDA approval?
The FDA approved Vumerity on October 22, 2019. [1]
What is the difference between Vumerity and other MS treatments?
Vumerity is an oral medication that selectively targets the Nrf2 pathway, a mechanism distinct from many other MS therapies that focus on modulating the immune system more broadly. [1] While Vumerity is approved for relapsing forms of MS, other treatments may target different disease courses or have different administration routes.
How effective is Vumerity in clinical trials?
In a Phase 3 clinical trial, Vumerity demonstrated a significant reduction in the annualized relapse rate compared to placebo in patients with relapsing MS. It also showed a reduction in the number of gadolinium-enhancing MRI lesions. [1]
What are the potential side effects of Vumerity?
Common side effects reported with Vumerity include flushing, nausea, diarrhea, and abdominal pain. More serious but less common side effects can also occur. [1] Patients should discuss any concerns about side effects with their healthcare provider.
Are there any contraindications for Vumerity?
Vumerity is contraindicated in patients with known hypersensitivity to bafcitelin or any of its excipients. [1]
Who manufactures Vumerity?
Vumerity is manufactured by Biogen. [1]
Where can I find more information on Vumerity's patent status?
Information regarding the patent exclusivity for Vumerity and other pharmaceuticals can be found on resources like DrugPatentWatch.com. [2]
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/vumerity-bafcitelin
[2] https://drugpatentwatch.com/